Eliem Therapeutics, Inc. ELYM
We take great care to ensure that the data presented and summarized in this overview for Eliem Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELYM
View all-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.23% of portfolio
-
Janus Henderson Group PLC London, X03.61MShares$14.8 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million7.7% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$10.7 Million0.7% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.17MShares$8.92 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.52MShares$6.27 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.32% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY1.23MShares$5.05 Million4.45% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD673KShares$2.76 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA651KShares$2.68 Million0.0% of portfolio
Latest Institutional Activity in ELYM
Top Purchases
Top Sells
About ELYM
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Insider Transactions at ELYM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2024
|
Emily Pimblett CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,191
-6.81%
|
$9,528
$8.12 P/Share
|
|
Sep 18
2024
|
Emily Pimblett CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+36.35%
|
-
|
|
Jul 22
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
69,005
-43.9%
|
$552,040
$8.03 P/Share
|
|
Jul 19
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
60,201
-19.81%
|
$421,407
$7.17 P/Share
|
|
Jul 18
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
38,576
-19.38%
|
$231,456
$6.93 P/Share
|
|
Jul 17
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
3,207
-1.59%
|
$19,242
$6.91 P/Share
|
|
Jul 16
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
50,000
-19.82%
|
$350,000
$7.13 P/Share
|
|
Jul 15
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
42,377
-14.38%
|
$296,639
$7.01 P/Share
|
|
Jul 12
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
50,000
-14.51%
|
$350,000
$7.07 P/Share
|
|
Jul 11
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
50,000
-12.67%
|
$350,000
$7.11 P/Share
|
|
Jul 10
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
50,000
-11.24%
|
$300,000
$6.83 P/Share
|
|
Jul 09
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
5,931
-1.32%
|
$35,586
$6.66 P/Share
|
|
Jul 05
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
12,342
-2.67%
|
$86,394
$7.06 P/Share
|
|
Jul 03
2024
|
Valerie Morisset EVP, R&D AND CSO |
SELL
Open market or private sale
|
Direct |
50,000
-9.75%
|
$300,000
$6.76 P/Share
|
|
Jul 01
2024
|
Valerie Morisset EVP, R&D AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,649
+1.47%
|
-
|
|
Jun 27
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
13,008,546
+30.34%
|
$39,025,638
$3.84 P/Share
|
|
Jun 27
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
5,259,872
+35.92%
|
-
|
|
Jun 27
2024
|
Stephen Basil Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
103,907
+50.0%
|
-
|
|
Jun 20
2024
|
Emily Pimblett CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,245
-24.9%
|
$8,715
$7.21 P/Share
|
|
Jun 18
2024
|
Emily Pimblett CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.36M shares |
|---|---|
| Open market or private purchase | 13M shares |
| Exercise of conversion of derivative security | 35.5K shares |
| Open market or private sale | 484K shares |
|---|